Literature DB >> 8385586

Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients.

M Ehrenstein1, C Longhurst, D A Isenberg.   

Abstract

This study compares recently devised methods for producing IgG anti-DNA MoAbs from patients with SLE and analyses the antibodies generated from one patient at different phases of disease. Lymphocytes from SLE patients were transformed with Epstein-Barr virus(EBV) and/or fused with a heteromyeloma cell line, CB-F7. Direct fusion with CB-F7 resulted in the highest proportion of IgG-secreting lines, whereas EBV transformation resulted in a high percentage of IgM-secreting lines. Using direct fusion, five IgM anti-DNA antibody-secreting hybridomas were generated using lymphocytes from a patient with relatively inactive SLE. Six months later when the disease was active, only IgG anti-DNA antibodies were produced. The antigen-binding patterns of the MoAbs were analysed. Only one of the IgM anti-DNA antibodies reacted with dsDNA by ELISA and none by Crithidia immunofluorescence, whereas two of the IgG antibodies reacted with dsDNA by ELISA and Crithidia but did not bind to ssDNA. Only the two IgG high affinity anti-dsDNA antibodies bound to histones, and this was enhanced by added DNA, whereas three IgM antibodies bound to cardiolipin. This study supports the notion that MoAbs derived from a patient with SLE represent those found in the serum of SLE patients at different stages of disease activity. The binding to histones by the two IgG anti-dsDNA antibodies supports the recently expressed view that antibodies binding DNA/histone may be important in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385586      PMCID: PMC1554857          DOI: 10.1111/j.1365-2249.1993.tb05945.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus.

Authors:  R Grunow; S Jahn; T Porstmann; S S Kiessig; H Steinkellner; F Steindl; D Mattanovich; L Gürtler; F Deinhardt; H Katinger
Journal:  J Immunol Methods       Date:  1988-02-10       Impact factor: 2.303

2.  Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum.

Authors:  J Sabbaga; O G Pankewycz; V Lufft; R S Schwartz; M P Madaio
Journal:  J Autoimmun       Date:  1990-04       Impact factor: 7.094

Review 3.  Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.

Authors:  P Casali; A L Notkins
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG).

Authors:  D P Symmons; J S Coppock; P A Bacon; B Bresnihan; D A Isenberg; P Maddison; N McHugh; M L Snaith; A S Zoma
Journal:  Q J Med       Date:  1988-11

5.  Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.

Authors:  B Friguet; A F Chaffotte; L Djavadi-Ohaniance; M E Goldberg
Journal:  J Immunol Methods       Date:  1985-03-18       Impact factor: 2.303

6.  Antibody producing human-human hybridomas. I. Technical aspects.

Authors:  L Olsson; H Kronstrøm; A Cambon-De Mouzon; C Honsik; T Brodin; B Jakobsen
Journal:  J Immunol Methods       Date:  1983-06-24       Impact factor: 2.303

7.  Analysis of autoantibody reactivity and common idiotype PR4 expression of myeloma proteins.

Authors:  R A Watts; W Williams; S Le Page; A Norden; A Soltys; G Swana; I Addison; F C Hay; D A Isenberg
Journal:  J Autoimmun       Date:  1989-10       Impact factor: 7.094

8.  DNA-anti-DNA complexes account for part of the antihistone activity found in patients with systemic lupus erythematosus.

Authors:  J L Subiza; A Caturla; D Pascual-Salcedo; M J Chamorro; E Gazapo; M A Figueredo; E G de la Concha
Journal:  Arthritis Rheum       Date:  1989-04

9.  Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone.

Authors:  P M Rumore; C R Steinman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

10.  Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes.

Authors:  D A Bell; B Morrison; P VandenBygaart
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

View more
  5 in total

1.  The role of somatic mutation in determining the affinity of anti-DNA antibodies.

Authors:  M Behrendt; L J Partridge; B Griffiths; M Goodfield; M Snaith; N J Lindsey
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

2.  Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV.

Authors:  Sanjeev Kumar; Karen A Bunting; Jatinderpal Kalsi; John A Hinks; David S Latchman; Laurence H Pearl; David A Isenberg
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

3.  Evidence for direct anti-heparin-sulphate reactivity in sera of SLE patients.

Authors:  K Pirner; A Rascu; W Nürnberg; A Rubbert; J R Kalden; B Manger
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

4.  Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype.

Authors:  M R Ehrenstein; C M Longhurst; D S Latchman; D A Isenberg
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity.

Authors:  Lesley J Mason; Anastasia Lambrianides; Joanna D Haley; Jessica J Manson; David S Latchman; David A Isenberg; Anisur Rahman
Journal:  Arthritis Res Ther       Date:  2005-06-10       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.